

Biohit Oyj Extraordinary general meeting and board of directors meeting decisions

Biohit Oyj Stock Exchange Release 10 March 2022 at 10:00 am local time (EET)

Biohit Oyj (“Company”) and Biohit HealthCare (Hefei) Co. Ltd. (“Hefei”) have on 8 February 2022 entered into a security agreement. Pursuant to such agreement, Hefei has pledged to the Company 1,500,000 class B shares in the Company as security for its obligations referred to therein (the “Hefei Pledge”).

Company’s extraordinary general meeting of shareholders has on 9 March 2022 resolved to authorize the Board of Directors to resolve on accepting a maximum total amount of 3,000,000 class B shares in the Company as pledge on the terms deemed fit by the Board of Directors.

Extraordinary general meeting also decided to authorize the Board of Directors to decide on the issue of a maximum total amount of 3,000,000 class B shares in the company by way of derogation from the shareholders’ pre-emptive subscription rights. The class B shares to be issued must consist of the own shares pledged to the company.

The Board of Directors of the Company decided on 9 March 2022, in accordance with the security agreement and authorization referred to above, resolved to accept the Hefei Pledge.

Additional information:

Päivi Siltala, CEO
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohit.fi

Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com